BioSpace News Archive

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company will be presenting at the BIO International Convention taking place June 13 - 16, 2022 in San Diego, California.

Teva to Present New Analyses of AJOVY ® (fremanezumab-vfrm) Injection and AUSTEDO ® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting.

Fortress Biotech, Inc. today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that on March 31, 2022, the Company completed the resubmission of its Biologics License Application (“BLA”) for 131 I-omburtamab (“omburtamab”) to the FDA.

Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27, 2022 , at 8:00 a.m. EDT.

The global Medical Devices Market was estimated USD 532.92 billion in 2021 and is set to reach USD 785.49 billion by 2030 and is estimated to expand at a CAGR of 6.7% during the prediction period 2022 to 2030.

Fluidigm Corporation announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP.

Legend Biotech Corporation today announced the appointment of Guowei Fang, Ph.D., as Senior Vice President, Global Head of Research and Early Development.

TCR2 Therapeutics Inc. announced that on March 31, 2022, the Compensation Committee of the Board of Directors of TCR2’s approved the grant of inducement stock options covering an aggregate of 73,000 shares of TCR2’s common stock to 9 new non-executive employees.

G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for an aggregate of 25,800 shares of G1’s common stock and an aggregate of 11,200 restricted stock units to four hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.